The unexpected therapeutic effects of CXCR2 CAR-T in the PDAC liver metastasis model may be due to the more exposed recognition of CXCL5 in metastatic tumors compared to the shielding of the stroma structure in primary tumors. This evidence concerns the gene CXCR2 and metastatic neoplasm.